22nd International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

随着抗逆转录病毒疗法（ART）的成功，合并症现在是主要原因 地球仪各地艾滋病毒感染者的死亡和残疾率，包括中低 收入国家（LMIC）。大型会议，如逆转录病毒会议和 艾滋病感染者大会和国际艾滋病学会大会，都是重要的会场 就艾滋病毒合并症研究的最新进展进行科学交流，但规模较小， 强调讨论和网络的更亲密的形式对职业生涯至关重要 科摩罗艾滋病毒调查人员的发展。共病国际研讨会 艾滋病毒药物不良反应，现在已经是第22个年头了，为<200名代表提供了一个 有机会聚在一起讨论艾滋病毒科摩罗的最新发现和争议 在一个房间里进行为期两天的研究。全体会议的发言人要么是来自外部的知名专家， 艾滋病毒研究或艾滋病毒研究人员在一个特定的科摩罗的专业知识。摘要 包括24场15分钟的演讲和海报展示会在内的演讲为以下人员提供了充足的机会： 研究人员介绍并获得他们最新工作的反馈。有了这个R13，我们建议 加强第22次讲习班（9月12日/13日，纽约），目标如下：1） 通过提供旅行奖学金，为LMIC最新的艾滋病研究提供论坛 向LMIC调查人员提供支持，支持国际公认的非传染性疾病专家 作为全体会议发言人，并与国际培训计划联络，2） 通过奖学金计划和研究技能培养来支持早期研究人员 讲习班，以及有导游的海报参观，3）通过 全体会议和摘要发言的网播。通过为越来越多的 来自世界各地的艾滋病毒科摩罗调查人员，我们希望催化未来 艾滋病毒合并症的研究工作，并促进研究结果转化为 临床策略，可以提高PLWH的寿命和健康寿命。

With the success of antiretroviral therapy (ART), comorbid diseases are now the leading causes of death and disability in people living with HIV around the globe, including low and middle income countries (LMIC). Large meetings, such as the Conference for Retroviruses and Opportunistic Infections and the International AIDS Society Conference, are important venues for scientific exchange regarding the latest advances in HIV Comorbidity research, but smaller, more intimate formats that emphasize discussion and networking are critical to the career development of HIV Comorbidity investigators. The International Workshop for Comorbidities and Adverse Drug Reactions in HIV, now in its 22nd year, provides <200 delegates with an opportunity to come together to discuss the latest findings and controversies in HIV Comorbidity research in one-room, two-day format. Plenary speakers are either noted experts from outside of HIV research or HIV researchers with expertise in a specific comorbidity. Abstract presentations including 24 15-minute talks and a poster session provide ample opportunity for researchers to present and get feedback on their latest work. With this R13, we propose to enhance the 22nd Workshop (September 12th/13th in New York) with the following aims: 1) to provide a forum for the latest HIV Comorbidity research in LMIC by offering travel scholarships to LMIC investigators, supporting an internationally-recognized expert in non-communicable diseases in LMIC as a plenary speaker, and liaising with international training programs, 2) to support early-stage investigators with a scholarship program and a research skill building workshop, and guided poster tour, 3) to increase the impact of the Workshop through the webcast of plenary and abstract presentations. By providing a “scientific home” to an increasing number of HIV Comorbidity investigators from around the world, we hope to catalyze future research efforts in HIV Comorbidities and facilitate the translation of research findings into clinical strategies that can improve the lifespan and health span of PLWH.